Furthermore, Etomoxir may rectify the imbalance of Th17 and Treg subpopulations by downregulating the mTOR/ACC1/CPT1A fatty acid oxidation signaling pathway, thereby mitigating HT. The gene discussed is MTOR; the disease is hematocrit.